Profile data is unavailable for this security.
About the company
IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimer’s. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer’s cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
- Revenue in USD (TTM)1.22m
- Net income in USD-14.15m
- Incorporated2005
- Employees61.00
- LocationIGC Pharma Inc2405 York Road, Suite 201LUTHERVILLE-TIMONIUM 21093-2264United StatesUSA
- Phone+1 (301) 983-0998
- Fax+1 (240) 465-0273
- Websitehttps://igcpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neurosense Therapeutics Ltd | 0.00 | -11.48m | 24.87m | 14.00 | -- | -- | -- | -- | -0.8568 | -0.8568 | 0.00 | -0.015 | 0.00 | -- | -- | 0.00 | -157.09 | -- | -208.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -205.37 | -- | -- | -- |
Forte Biosciences Inc | 0.00 | -31.48m | 25.34m | 9.00 | -- | 0.7163 | -- | -- | -1.19 | -1.19 | 0.00 | 0.9719 | 0.00 | -- | -- | 0.00 | -77.74 | -72.06 | -84.92 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
Arca Biopharma Inc | 0.00 | -5.34m | 25.52m | 4.00 | -- | 0.6894 | -- | -- | -0.3704 | -0.3704 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -13.19 | -27.78 | -13.49 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
Lisata Therapeutics Inc | 0.00 | -20.84m | 25.92m | 25.00 | -- | 0.5281 | -- | -- | -2.58 | -2.58 | 0.00 | 5.91 | 0.00 | -- | -- | 0.00 | -32.63 | -45.97 | -36.16 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
Biora Therapeutics Inc | 18.00k | -122.17m | 26.07m | 54.00 | -- | -- | -- | 1,448.56 | -9.56 | -9.59 | 0.0016 | -5.07 | 0.0004 | -- | 0.0219 | 333.33 | -251.08 | -- | -63,963.88 | -- | -- | -- | -678,727.80 | -- | -- | -- | -- | -- | -75.54 | -- | 72.65 | -- | -- | -- |
Sensei Biotherapeutics Inc | 0.00 | -34.10m | 26.32m | 27.00 | -- | 0.405 | -- | -- | -1.21 | -1.21 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -35.38 | -47.03 | -38.31 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0247 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
IGC Pharma Inc | 1.22m | -14.15m | 26.43m | 61.00 | -- | 2.82 | -- | 21.73 | -0.2479 | -0.2479 | 0.0217 | 0.142 | 0.0776 | 0.2084 | 7.09 | 19,934.43 | -90.30 | -33.35 | -100.90 | -35.84 | 51.40 | 8.74 | -1,163.24 | -410.26 | 0.8564 | -- | 0.0153 | -- | 129.47 | -16.11 | 23.38 | -- | 25.28 | -- |
Oncternal Therapeutics Inc | 785.00k | -39.48m | 26.64m | 27.00 | -- | 0.8829 | -- | 33.93 | -13.44 | -13.44 | 0.2672 | 10.19 | 0.0149 | -- | -- | 29,074.07 | -74.93 | -49.40 | -85.36 | -54.51 | -- | -- | -5,029.17 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
MEI Pharma Inc | 72.65m | 19.84m | 26.65m | 46.00 | 1.34 | 0.448 | 1.32 | 0.3669 | 2.98 | 2.98 | 10.90 | 8.93 | 0.6425 | -- | 25.47 | 1,579,304.00 | 17.55 | -25.31 | 20.31 | -28.59 | -- | -- | 27.32 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
Ayala Pharmaceuticals Inc | -100.00bn | -100.00bn | 27.29m | 14.00 | -- | -- | -- | -- | -- | -- | -- | -1.30 | -- | -- | -- | -- | -- | -56.14 | -- | -70.04 | -- | -- | -- | -462.10 | -- | -- | -- | -- | -92.28 | -53.92 | 13.87 | -- | -46.58 | -- |
Sol Gel Technologies Ltd | 1.55m | -27.24m | 27.30m | 36.00 | -- | 0.7065 | -- | 17.57 | -1.02 | -1.02 | 0.0574 | 1.39 | 0.0338 | -- | 0.3774 | 43,166.67 | -59.27 | -31.60 | -64.80 | -35.49 | -- | -- | -1,752.77 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
Unity Biotechnology Inc | 0.00 | -52.53m | 27.53m | 32.00 | -- | 0.662 | -- | -- | -3.65 | -3.65 | 0.00 | 2.48 | 0.00 | -- | -- | 0.00 | -51.08 | -51.33 | -58.28 | -57.56 | -- | -- | -- | -7,431.69 | -- | -159.24 | 0.00 | -- | -95.07 | -29.78 | 1.31 | -- | -43.65 | -- |
Lipocine Inc | -2.85m | -16.35m | 27.64m | 17.00 | -- | 1.36 | -- | -- | -3.11 | -3.11 | -0.5417 | 3.83 | -0.0942 | -- | -- | -167,695.30 | -54.02 | -39.32 | -58.16 | -45.87 | -- | -- | -- | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
Brainstorm Cell Therapeutics Inc | 0.00 | -16.63m | 27.66m | 43.00 | -- | -- | -- | -- | -0.4367 | -0.4367 | 0.00 | -0.057 | 0.00 | -- | -- | 0.00 | -175.67 | -108.79 | -907.12 | -197.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.736 | -- | -30.59 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 717.88k | 1.13% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 630.22k | 0.99% |
Geode Capital Management LLCas of 31 Dec 2023 | 324.30k | 0.51% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 184.11k | 0.29% |
Dearborn Partners LLCas of 31 Dec 2023 | 116.71k | 0.18% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 71.36k | 0.11% |
Bridgeway Capital Management LLCas of 31 Dec 2023 | 69.00k | 0.11% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 65.50k | 0.10% |
Virtu Americas LLCas of 31 Dec 2023 | 60.72k | 0.10% |
Group One Trading LPas of 31 Dec 2023 | 60.46k | 0.10% |